Patent Issuance: In May 2025, Surrozen was granted U.S. Patent No. 12,297,278 by the U.S. Patent and Trademark Office, covering its SWAP™ technology for creating multi-specific Wnt surrogate molecules ...

Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development Surrozen forms Clinical Advisory Board comprised of leading retinal specialists Data Presentations at Association for ...

I switched statin after 25 years of simvastatin. The complications from the change have left me with lasting organ damage.

June 30, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage ...

D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...

Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected by Q4 2025 (including a three-month ...

Key Points Surrozen reported GAAP EPS of $2.55 for Q2 2025, exceeding expectations by $3.66 per share (GAAP) due to significant one-time and non-cash gains. Surrozen recorded $1.0 million in research ...

For most people, floaters are completely normal and part of the eye aging process, says Dr. Kelly. They’re especially common ...

Every now and then, a bit of nostalgia bait drifts across my social media feed, with people pining for the brighter colors of ...

REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2025.

As we age, our skin starts losing its elasticity, and our bones begin to lose their strength. One of the main reasons behind ...